Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PHAR Stock Forecast 2026-2027
$13.29
Current Price
$947.44M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PHAR Price Targets
+201.0%
To High Target of $40.00
+178.4%
To Median Target of $37.00
+76.1%
To Low Target of $23.40
PHAR Price Momentum
-4.1%
1 Week Change
+5.1%
1 Month Change
+28.9%
1 Year Change
-24.8%
Year-to-Date Change
-37.7%
From 52W High of $21.34
+39.4%
From 52W Low of $9.54
📊 TOP ANALYST CALLS
Did PHAR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Pharming is one of their latest high-conviction picks.
Latest PHAR Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, PHAR has a bullish consensus with a median price target of $37.00 (ranging from $23.40 to $40.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $13.29, the median forecast implies a 178.4% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PHAR Analyst Ratings
4
Buy
0
Hold
0
Sell
PHAR Price Target Range
Low
$23.40
Average
$37.00
High
$40.00
Current: $13.29
Latest PHAR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PHAR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2026 | Canaccord Genuity | Whitney Ijem | Buy | Initiates | $37.00 |
| Mar 24, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 13, 2026 | Oppenheimer | Outperform | Reiterates | $N/A | |
| Mar 21, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 20, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 14, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Mar 14, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 17, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 16, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 11, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 9, 2024 | Jefferies | Buy | Initiates | $N/A | |
| Oct 28, 2024 | Oppenheimer | Outperform | Maintains | $N/A | |
| Oct 24, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 10, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 26, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 1, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 31, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 14, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 3, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Pharming Group N.V. - ADR (PHAR) Competitors
The following stocks are similar to Pharming based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Pharming Group N.V. - ADR (PHAR) Financial Data
Pharming Group N.V. - ADR has a market capitalization of $947.44M with a P/E ratio of 72.5x. The company generates $369.49M in trailing twelve-month revenue with a 3.3% profit margin.
Revenue growth is -8.4% quarter-over-quarter, while maintaining an operating margin of -6.8% and return on equity of +5.0%.
Valuation Metrics
Market Cap
$947.44M
Enterprise Value
$978.20M
P/E Ratio
72.5x
PEG Ratio
-1.1x
Price/Sales
2.6x
Growth & Margins
Revenue Growth (YoY)
-8.4%
Gross Margin
+90.8%
Operating Margin
-6.8%
Net Margin
+3.3%
EPS Growth
-8.4%
Financial Health
Cash/Price Ratio
+17.2%
Current Ratio
2.6x
Debt/Equity
43.2x
ROE
+5.0%
ROA
+4.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Pharming Group N.V. - ADR (PHAR) Business Model
About Pharming Group N.V. - ADR
What They Do
Develops innovative medicines for rare diseases.
Business Model
Pharming Group N.V. generates revenue by commercializing and developing specialized biopharmaceuticals, primarily focusing on protein replacement therapies and precision medicines. The company markets its lead products, such as RUCONEST and Joenja, and is advancing a pipeline of investigational therapies, which allows it to address significant unmet medical needs in rare diseases.
Additional Information
Founded in 1988 and headquartered in Leiden, Netherlands, Pharming operates in over 30 markets globally. The company utilizes specialized bioprocessing techniques and collaborates with various partners for research, development, and commercialization efforts, highlighting its commitment to innovation in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
404
CEO
Mr. Fabrice Chouraqui Ph.D., Pharm.D.
Country
Netherlands
IPO Year
2020
Website
www.pharming.comPharming Group N.V. - ADR (PHAR) Latest News & Analysis
Latest News
Quick Summary
Pharming Group N.V. will release preliminary financial results for Q2 and H1 2026, along with a business update, on July 30, 2026.
Why It Matters
Pharming's upcoming financial report and business update could influence stock performance, impacting investor sentiment and expectations regarding growth and profitability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pharming announced the FDA accepted its sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 with APDS.
Why It Matters
FDA acceptance of Pharming's sNDA for Joenja® could expand its market, potentially increasing revenue and boosting investor confidence in the company's growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York
1 month ago
Quick Summary
Pharming Group will participate in a Fireside Chat at the 2026 Jefferies Global Healthcare Conference in New York on June 4, 2026, at 11:05 EDT.
Why It Matters
Pharming Group's participation in a major healthcare conference signals potential insights into its strategies and growth, impacting investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pharming Group's shareholders approved all proposals at the Annual General Meeting held on May 28, 2026.
Why It Matters
Approval of all proposals at Pharming's AGM can indicate strong shareholder support and confidence in the company’s strategy, potentially boosting stock performance and attracting new investments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Pharming Group Q1 Earnings Call Highlights
2 months ago
Quick Summary
Pharming Group reported a decline in Q1 2026 RUCONEST revenue due to inventory movements and exiting non-U.S. markets, while Joenja showed strong growth and pipeline advancements.
Why It Matters
Pharming Group's revenue drop from RUCONEST signals potential volatility, but strong growth in Joenja and pipeline advancements may offset concerns, impacting investor sentiment and future valuations.
Source: MarketBeat
Market Sentiment:
Neutral
Quick Summary
Pharming Group N.V. (PHAR) held its Q1 2026 earnings call, discussing financial performance and strategies. Detailed insights on revenue and forecasts were shared.
Why It Matters
Pharming Group's Q1 2026 earnings reveal financial performance, trends, and future guidance, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About PHAR Stock
What is Pharming Group N.V. - ADR's (PHAR) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Pharming Group N.V. - ADR (PHAR) has a median price target of $37.00. The highest price target is $40.00 and the lowest is $23.40.
Is PHAR stock a good investment in 2027?
According to current analyst ratings, PHAR has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.29. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PHAR stock?
Wall Street analysts predict PHAR stock could reach $37.00 in the next 12 months. This represents a 178.4% increase from the current price of $13.29. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pharming Group N.V. - ADR's business model?
Pharming Group N.V. generates revenue by commercializing and developing specialized biopharmaceuticals, primarily focusing on protein replacement therapies and precision medicines. The company markets its lead products, such as RUCONEST and Joenja, and is advancing a pipeline of investigational therapies, which allows it to address significant unmet medical needs in rare diseases.
What is the highest forecasted price for PHAR Pharming Group N.V. - ADR?
The highest price target for PHAR is $40.00 from at , which represents a 201.0% increase from the current price of $13.29.
What is the lowest forecasted price for PHAR Pharming Group N.V. - ADR?
The lowest price target for PHAR is $23.40 from at , which represents a 76.1% increase from the current price of $13.29.
What is the overall PHAR consensus from analysts for Pharming Group N.V. - ADR?
The overall analyst consensus for PHAR is bullish. Out of 2 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $37.00.
How accurate are PHAR stock price projections?
Stock price projections, including those for Pharming Group N.V. - ADR, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 3:04 AM UTC